CELLPROTHERA

CellProthera starts PERFECT study to assess long-term safety and efficacy of ProtheraCytes in heart attack patients, following positive EXCELLENT trial results.

Industry leaders discussed key challenges and innovations in cell and gene therapy (CGT), emphasizing patient engagement, scaling production, navigating global markets, and supply chain complexities. They highlighted the importance of early planning, technological advancements, and collaboration to overcome hurdles and ensure CGT's potential in revolutionizing healthcare.

CellProthera plans a pivotal phase III trial in the US and Europe for its ProtheraCytes cell therapy, following FDA alignment, to prevent heart diseases post-acute myocardial infarction (AMI).

CellProthera's positive pre-IND meeting with FDA paves way for Phase III trial of ProtheraCytes, a cell therapy for myocardial infarction. The trial, with a two-year follow-up, aims to prevent subsequent heart diseases. The company plans to pursue RMAT designation for expedited development and review.